Vanda Pharma reports interim results from Phase 3 COVID-19 trial

Vanda Pharmaceuticals

Vanda Pharmaceuticals (NASDAQ:VNDA) reported interim results from its Phase 3 trial assessing tradipitant for the treatment of COVID-19 pneumonia.

The data are based on the first 60 patients enrolled in the study, who received either tradipitant, a neurokinin-1 receptor antagonist, or placebo.

The interim analysis showed that 57% of patients who received tradipitant improved, compared with 50% of patients who received placebo. The mortality rate of patients who received tradipitant was 14.2%, compared with 16.6% of patients who received placebo.

In the time-to-improvement analysis conducted after seven days of treatment, patients treated with tradipitant recovered earlier than those receiving placebo.

“These results, albeit preliminary, are exciting, offering the promise of a significant contribution in the treatment of COVID-19 and the prospect of making tradipitant part of the standard-of-care in accelerating recovery for patients with COVID-19 pneumonia,” Dr. Mihael Polymeropoulos, Vanda’s president and CEO, said in a statement.

The study is being conducted at New York City’s Lenox Hill Hospital in collaboration with The Feinstein Institutes for Medical Research and is expected to enrol some 300 patients.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.